Cargando…
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat...
Autores principales: | Feng, Weiguo, Zhang, Meng, Wu, Zhuo-Xun, Wang, Jing-Quan, Dong, Xing-Duo, Yang, Yuqi, Teng, Qiu-Xu, Chen, Xuan-Yu, Cui, Qingbin, Yang, Dong-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330633/ https://www.ncbi.nlm.nih.gov/pubmed/32670878 http://dx.doi.org/10.3389/fonc.2020.00955 |
Ejemplares similares
-
Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019) -
NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance
por: Zhang, Meng, et al.
Publicado: (2020) -
Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020) -
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019) -
VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)